Cutaneous leishmaniasis: an underdiagnosed entity in the first contact

Authors

  • Andrea Sierra Franco Hospital General Regional #45 IMSS, Guadalajara, Jalisco, México
  • María Jimena Talamante Madrid Hospital General de Zona #2 IMSS, Hermosillo, Sonora, México
  • Reneta Montserrat Espejo Nuño Universidad Autónoma de Guadalajara, Guadalajara, Jalisco, México
  • Daniela Alejandra Davila Baeza Universidad Autónoma de Guadalajara, Guadalajara, Jalisco, México
  • Martha Yanelly Espinoza Hernández Hospital General de Zona No. 2 Dr. Efrén Correa Magallanes, Fresnillo, Zacatecas, México
  • Edit Cano Muñoz Facultad de Estudios Superiores Zaragoza de la Universidad Nacional Autónoma de México, Ciudad de México, México
  • María Erika Boza Medrano Universidad Juárez del Estado de Durango, Durango, México

DOI:

https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20231013

Keywords:

Skin, Dermatology, Infection, Leishmaniasis

Abstract

Leishmaniasis is a chronic, vector-borne parasitic disease caused by a flagellated protozoan of the genus Leishmania, which has more than 20 species. Usually, it is a disease that affects the tropical and subtropical populations of the world. The disease is transmitted through the bite of female mosquitoes of the genus Lutzomyiaen and Phlebotomusen. The clinical presentation and its manifestations are variable, they are affected by the species and immunological state of the host. Generally, three main types are distinguished: the most frequent presentation and with the best prognosis is cutaneous leishmaniasis (CL), the second is known as mucocutaneous leishmaniasis (MCL), and the third presentation is visceral leishmaniasis, which puts endanger the life of the person presenting it. Leishmaniasis is related to various risk factors, including: poverty, malnutrition, migration, and inadequate housing conditions; in addition, people who work in rural areas, such as farmers, farmers, or the military in endemic areas, are at greater risk of suffering a bite by a transmitting mosquito. Due to its variable manifestations and greater affectation in poor areas, it is a pathology that is normally overlooked. The objective of this review is to define and differentiate the most frequent types of presentation as well as their cutaneous manifestations, and to provide extensive information on diagnostic methods. Briefly, general information on the pathology and treatment of these lesions will be provided.

Metrics

Metrics Loading ...

References

Aronson NE, Joya CA. Cutaneous Leishmaniasis: Updates in Diagnosis and Management. Infect Dis Clin North Am. 2019;33(1):101-17.

Mirzaei A, Maleki M, Masoumi E, Maspi N. A historical review of the role of cytokines involved in leishmaniasis. Cytokine. 2021;145(155297):155297.

Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet. 2018;392(10151):951-70.

Hidalgo Solís MJ, Víquez Redondo KF, Barrantes Valverde SM. Leishmaniasis cutánea. Rev Méd Sinerg. 2021;6(5):e674.

Aronson N. Cutaneous leishmaniasis: Clinical manifestations and diagnosis. UpToDate-Evidence-based Clinical Decision Support, Wolters Kluwer. Available at: https://www.uptodate. com/contents/cutaneous-leishmaniasis-clinical-manifestations-and-diagnosis?search=Cutaneous %20Leishmaniasis&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1. Accessed on 21 January 2023.

Bern C. Visceral leishmaniasis: Clinical manifestations and diagnosis. UpToDate-Evidence-based Clinical Decision Support, Wolters Kluwer. Available at: https://www.uptodate. com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis. Accessed on 21 January 2023.

Mock DJ, Hollenbaugh JA, Daddacha W. Leishmania induces survival, proliferation and elevated cellular dNTP levels in human monocytes promoting acceleration of HIV co-infection. PLoS Pathog. 2012;8:e1002635.

Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004;27:305-18.

Isenring E, Fehr J, Gültekin N. Infectious disease profiles of Syrian and Eritrean migrants presenting in Europe: a systematic review. Travel Med Infect Dis. 2018;25:65-76.

Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet. 2018;392:951-70.

Uzun S, Gürel MS, Durdu M. Clinical practice guidelines for the diagnosis and treatment of cutaneous leishmaniasis in Turkey. Int J Dermatol. 2018;57:973-82.

Centers for Disease Control and Prevention. Practical guide for specimen collection and reference diagnosis of leishmaniasis. Available at: https://www.cdc.gov/parasites/leishmaniasis/resources/pdf/cdc_- diagnosis_guide_leishmaniasis_2015 .pdf. Accessed on 21 January 2023.

World Health Organization. Neglected tropical diseases. Available at: https://www.who.int/ neglected_diseases/diseases/en/. Accessed January 21, 2023.

Pace D. Leishmaniasis. J Infect. 2014;69(1):S10-18.

Hayani K, Dandashli A, Weisshaar E. Cutaneous leishmaniasis in Syria: clinical features, current status and the effects of war. Acta Derm Venereol. 2015;95:62-6.

Alasaad S. War diseases revealed by the social media: massive leishmaniasis outbreak in the Syrian Spring. Parasit Vectors. 2013;6:94.

Inci R, Ozturk P, Mulayim MK. Effect of the Syrian civil war on prevalence of cutaneous leishmaniasis in Southeastern Anatolia, Turkey. Med Sci Monit. 2015;21:2100-4.

Bravo FG. Protozoa and worms. In: Bolognia JL, Schaffer JV, Cerroni L, eds. Dermatology. 4th ed. China Elsevier. 2018;1470-502.

Wright NA, Davis LE, Aftergut KS. Cutaneous leishmaniasis in Texas: a northern spread of endemic areas. J Am Acad Dermatol. 2008;58:650-52.

McIlwee BE, Weis SE, Hosler GA. Incidence of endemic human cutaneous leishmaniasis in the United States. JAMA Dermatol. 2018;154:1032-9.

Downloads

Published

2023-04-04

Issue

Vol. 9 No. 3 (2023): May-June 2023

Section

Review Articles